Ledipasvir: all 25 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Ledipasvir/Sofosbuvir for Hepatitis B Virus InfectionCompletedNCT03312023Phase 2Results posted
- Hepatitis C Virus(HCV) Heart and Lung StudyCompletedNCT02858180Phase 4Results posted
- Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) StudyTerminatedNCT02717949Phase 4Results posted
- Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)TerminatedNCT02503735Not applicableResults posted
- A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 InfectionCompletedNCT02421211Phase 2Results posted
- Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIVCompletedNCT01878799Phase 2Results posted
- Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard TreatmentCompletedNCT04530422Phase 3
- Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19CompletedNCT04498936Phase 4
- PK of SOF/LED in HCV - Infected Adolescents With Haematological DisordersStatus unknownNCT04353986Phase 3
- Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.WithdrawnNCT03279133Phase 4
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionCompletedNCT02992457Phase 4
- Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing WorldCompletedNCT02964091Phase 4
- DAA in the Risk of Recurrence After Curative Treatment of HCCWithdrawnNCT02959359Phase 4
- Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV InfectionCompletedNCT02836925Phase 2
- Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCCCompletedNCT02771405Phase 3
- Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C)CompletedNCT02768961Phase 4
- Extrahepatic Insulin Resistance in Chronic Hepatitis CCompletedNCT02760355Not applicable
- Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1CompletedNCT02705534Phase 3
- Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infectionCompletedNCT02480387Phase 2
- Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)TerminatedNCT02478229Phase 3
- Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central AfricaCompletedNCT02405013Phase 2
- GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC GenotypeTerminatedNCT01384383Phase 2
- Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus InfectionCompletedNCT01371578Phase 2
- GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) InfectionCompletedNCT01353248Phase 2
- A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CCompletedNCT01193478Phase 1